Pancreatic Cancer Clinical Trials in Scottsdale, Arizona
6 studies are recruiting for pancreatic cancer in Scottsdale, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- HonorHealth Research Institute, Scottsdale, Arizona
- Locations
- 86 in total
- Run by
- Revolution Medicines, Inc.
-
AOH1996 for the Treatment of Refractory Solid Tumors
This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Honor Health Research and Innovation Institute, Scottsdale, Arizona
- Locations
- 3 in total
- Run by
- City of Hope Medical Center
-
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- HonorHealth Research Institute, Scottsdale, Arizona
- Locations
- 5 in total
- Run by
- Revolution Medicines, Inc.
-
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Honor Health Research Institute, Scottsdale, Arizona
- Locations
- 82 in total
- Run by
- Revolution Medicines, Inc.
-
Pancreatic Cancer Detection Consortium
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Honorhealth, Scottsdale, Arizona
- Locations
- 13 in total
- Run by
- City of Hope Medical Center
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- HonorHealth Medical Group, Scottsdale, Arizona
- Locations
- 2 in total
- Run by
- Medical College of Wisconsin
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.